Sorry, you need to enable JavaScript to visit this website.

FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™

NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). The interchangeable designation applies to all approved indications of ABRILADA, including certain patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.

September Social Media Round-Up—DEI, CMO, and Rocky Mount Resumes

Albert Bourla sitting at a roundtable discussion

This September, Albert Bourla, Pfizer’s CEO, attended Black Corporate Directors Conference to discuss minority representation across all sectors, and our social roundup starts with his thoughts on their mission. Our Chief Marketing Officer discusses his first year as Pfizer’s first CMO and where we go from here. It’s an illuminating read from an innovative thinker.

Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due To The Potential For Presence of Glass Particulate Matter

Media Contact:  
Media Relations
+1- 212-733-1226
[email protected]

FOR IMMEDIATE RELEASE - October 2, 2023 - NEW YORK, NY.,

Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed in the table below of 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10mL vial; 1% Lidocaine HCl Injection, USP, 50 mg/5mL vial; and 2% Lidocaine HCl Injection, USP, 100 mg/5mL vial to the user level. The recall was initiated due to the potential for presence of glass particulate matter. 

Meet 6 of the 20 Organizations Making an Impact Through the Global Health Innovation Grants Program

Since 2016, The Pfizer Foundation’s* Global Health Innovation Grants (GHIG) program has supported community-based initiatives that aim to improve quality of care and strengthen health systems in lower income countries. Now in its seventh year, 20 new recipients of the one-year grant program have each received US $100,000 to drive innovative solutions that help address vaccine-preventable illness in their communities.

Helping UC Patients to “Live Fully” with Sunny Anderson

When it comes to understanding certain aspects of disease states and health conditions, there is no substitute for patient experience. That’s why Pfizer is so dedicated to communicating with and learning from patients. We are especially grateful for collaborations with patients who use their personal platforms to advocate for and educate the public about the conditions they live with every single day.

Pfizer’s Rocky Mount Facility Restarts Production Amid First Phase of Post-Tornado Recovery Efforts

NEW YORK, September 25, 2023 – Pfizer Inc. (NYSE: PFE) has restarted the majority of its manufacturing lines at the Rocky Mount, North Carolina facility following severe damage from a tornado that hit the site on July 19. The resumption of production also includes the launch of one line in the site’s new sterile injectable manufacturing area referred to as R3, a state-of the-art module approved earlier this year by the U.S. Food and Drug Administration (FDA). This expedited restart is a proud achievement for the Rocky Mount team; however, it is only the first step toward full recovery for the plant, as Pfizer restarts production through a phased approach, with full production across the site’s three manufacturing suites anticipated by the end of 2023. 
Subscribe to Updates